


<b>AMENDMENT TRANSMITTAL LETTER (Small Entity)</b>				Docket No. <b>PM (DC-0251)</b>	
Applicant(s): <b>Wade and Demian</b>					
Application No. <b>09/720,078</b>	Filing Date <b>July 25, 2001</b>	Examiner <b>Phillip Gambel</b>	Customer No. <b>26259</b>	Group Art Unit <b>1644</b>	Confirmation No. <b>7302</b>
Invention: <b>METHODS AND COMPOSITIONS FOR MODULATING ANTIGEN-SPECIFIC IMMUNOLOGICAL (HUMORAL) RESPONSES BY TARGETING SUCH ANTIGEN TO APCs IN CONJUNCTION WITH ANTI-CD40 LIGAND ADMINISTRATION</b>					
<u>COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	6 -	31 =	0	x \$25.00	\$0.00
INDEP. CLAIMS	1 -	4 =	0	x \$100.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>50-1619</b> <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 _____ Signature			Dated: <b>November 27, 2006</b>		
<b>Jane Massey Licata</b> <b>Reg. No. 32,257</b> <b>Licata &amp; Tyrrell P.C.</b> <b>66 E. Main Street</b> <b>Marlton, NJ 08053</b> <b>Tel: 856-810-1515</b> <b>Fax: 856-810-1454</b>			I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ _____ (Date)		
CC:			Signature of Person Mailing Correspondence		
			Typed or Printed Name of Person Mailing Correspondence		

RESPONSE UNDER 37 CFR §1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: PM (DC-0251)  
Inventor: Wade and Demian  
Serial No.: 09/720,078  
Filing Date: July 25, 2001  
Examiner: Gambel, Phillip  
Customer No.: 26259  
Group Art Unit: 1644  
Confirmation No.: 7302  
Title: Methods and Compositions for Modulating  
Antigen-Specific Immunological (Humoral)  
Responses by Targeting Such Antigen to  
APCs in Conjunction with Anti-CD40  
Ligand Administration

Electronically Submitted via EFS-Web  
Date: November 27, 2006

I hereby certify that this paper is being electronically  
submitted on the date indicated above to the  
Commissioner for Patents, U.S. Patent &  
Trademark Office (AF).

By Jane Massey Licata  
Typed Name: Jane Massey Licata, Reg. No. 32,257

Commissioner for Patents  
U.S. Patent & Trademark Office  
(AF)

Dear Sir:

Reply Under 37 C.F.R. §1.116

This is a reply to the Office Action mailed September 13,  
2006 setting a three (3) month statutory period for response.  
Please enter the following amendments and remarks into the  
record.

Attorney Docket No.: DC-0251  
Inventor: Wade and Demian  
Serial No.: 09/720,078  
Filing Date: July 25, 2001  
Page 2

**Amendments to the Claims** are reflected in the listing of claims which begin on page 3 of this paper.

**Remarks/Arguments** begin on page 5 of this paper.